
Industrials · Industrial Machinery & Supplies & Components
$111.75
+2.80%
Vol: 106K
Monday, June 15, 2026
No material news in the last 48 hours.
Xylem (XYL) is back in focus after agreeing to design, build, and operate a full-cycle advanced water system at Dow's large-scale industrial complex in Fort Saskatchewan, Alberta, Canada, with the system expected to be operational by August 2028. The long-term build-own-operate arrangement is being read by some analysts as a recurring-revenue catalyst supporting an undervaluation thesis after a weak stretch for the shares. On June 14, 2026, XYL traded between roughly $108.80 and $110.41, near a market cap of about $26.2B, with the stock down about 20.5% year-to-date and a one-year total shareholder return of about -13.2%. The average analyst price target sits around $169 (range $130 to $182), implying significant upside versus the depressed price. The bear case is that the Alberta system does not contribute until 2028, so near-term financials are unchanged while broad industrial/water demand softness, portfolio divestitures (e.g., AURELIUS buying the international metering division), and multiple compression continue to weigh on the stock.
Xylem directors Jerome Peribere and Mark Morelli each acquired 1,711 shares ($400K total) at $116.88 on May 14, the same day shareholders re-elected the nine-member board, ratified Deloitte as auditor, and approved the 2026 Employee Stock Purchase Plan. Earlier, Peribere bought 1,210 shares at $116.61 on May 4. The Board declared a $0.43 Q2 dividend payable June 25 (record date May 28). Stock traded $106-108 on May 20. The company revised full-year revenue guidance upward (+2-3% growth) following a Q1 EPS beat ($1.12 vs $1.09). Risk: insider sell from CAO Geri-Michelle McShane (3,147 shares at $86.76 on May 7) cuts against the directors bullish signal.
Xylem held its 2026 Annual Meeting on May 14, 2026 with 88.12% of outstanding shares represented. Shareholders elected nine directors to one-year terms, ratified Deloitte & Touche as independent auditor, approved executive compensation on an advisory basis, and endorsed the 2026 Employee Stock Purchase Plan. Insider activity was notable: on May 14, directors Jerome Peribere and Mark Morelli each bought 1,711 shares (3,422 total worth ~$400K at $116.88). Earlier, Peribere also purchased 1,210 shares on May 4 at $116.61. Officer Geri-Michelle McShane sold 3,147 shares on May 7 at $86.76. Shares traded near $106 on May 20. Analyst consensus remains Buy with the most recent rating a Hold at $135 price target.
No material news in the last 48 hours.
Xylem saw notable insider activity in early May: Director Jerome Peribere purchased 1,210 shares at $116.61 on May 4 (~$141K, raising his stake to 27,209 shares), while Senior VP and Chief Administrative Officer Geri-Michelle McShane sold 3,147 shares at $86.76 on May 7. Q1 2026 results showed adjusted EPS of $1.12 (up 14%) with net income of $193M and orders of $2.2B. The company raised its 2026 revenue guidance to $9.2-$9.3B and provided Q2 guidance of 2-3% reported revenue growth with EPS of $1.31-$1.36. Xylem participated in the Oppenheimer 21st Annual Industrial Growth Conference on May 7. Shares traded around $109.45 on May 13, down 21.1% YTD, with DCF analysis suggesting 31.8% undervaluation versus intrinsic value of $158.50.
Xylem trading around $109.45 on May 13 within a 52-week range of $108.97-$154.27. Insider activity was mixed: director Jerome Peribere purchased 1,210 shares at $116.61 on May 4 (signal of confidence at a depressed price), while Chief Administrative Officer Geri-Michelle McShane sold 3,147 shares at $86.76 on May 7 in an M-Exempt transaction. The moves follow Q1 2026 results where adjusted EPS reached $1.12 with net income of $193M and $2.2B in orders; Xylem now sees 2026 revenue of $9.2-9.3B and adjusted EPS of $5.35-$5.60. Xylem will present at the Oppenheimer 21st Annual Industrial Growth Conference. Sell-side remains constructive with 14 Buy ratings and roughly 37.8% upside to consensus targets.
Director Jerome Peribere acquired 1,210 Xylem shares at $116.61 on May 4 (~$141K) signaling insider confidence, while CAO Geri-Michelle McShane sold 3,147 shares at $86.76 on May 7. Xylem Q1 2026 EPS of $1.12 beat $1.09 estimate; revenue $2.13B slightly missed $2.11B forecast. Full-year revenue guide was raised to $9.2B-$9.3B. JPMorgan reaffirmed Buy on May 1. Stock at $109.45 on May 13, with consensus rating of Buy from 14 analysts.
No material news in last 48 hours.
Xylem saw mixed insider activity in early May, with director Jerome Peribere acquiring 1,210 shares at $116.61 on May 4 while SVP/CAO Geri-Michelle McShane sold 3,147 shares at $86.76 on May 7. The water technology company had reported strong Q1 2026 results on April 28 with EPS of $1.12 beating $1.09 consensus and revenue of $2.13 billion. Xylem raised its 2026 revenue guidance to $9.2-$9.3 billion. JPMorgan reaffirmed its Buy rating May 1 while Mizuho maintained Hold April 30. Shares trade around $112.37 with the stock up about 5% on the week despite a wider 90-day decline of 16.3%. Risk: insider selling and stock weakness over the past quarter could weigh on near-term sentiment.
Xylem reported Q1 2026 revenue of $2.13B vs $2.11B estimate and adjusted EPS of $1.12 vs $1.08, raising FY2026 revenue guidance to $9.2-9.3B. However, organic revenue was flat versus prior year, missing analyst expectations, with growth attributed to resilient demand in U.S. municipal and utility markets in Water Infrastructure and Measurement & Control Solutions. Stock fell to 52-week low near $114, trading at $113.76, down ~16% from start of 2026 (52-week range $113.45-$154.27). On May 4, Director Jerome Peribere bought 1,210 shares at $116.61 for $141,098, raising total holdings to 27,209 shares. J.P. Morgan reaffirmed Buy May 1; Mizuho maintained Hold April 30.
Xylem Inc. reported Q1 2026 earnings per share of $1.12 beating Wall Street estimate of $1.08 on sales of $2.1 billion. Net income margin improved 90 basis points to 9.1 percent and adjusted EBITDA margin reached 20.6 percent driven by productivity savings and strong price realization. Company announced $1.5B common stock repurchase authorization effective February 25, 2026. Full-year 2026 revenue guidance of approximately $9.2-$9.3 billion represents 2-3% growth on reported basis. Strategic initiatives include collaborations with utilities and Amazon in Mexico City and Monterrey deploying Xylem Vue advanced analytics platform. Company maintains anchor investment in Burnt Island Ventures funds focused on water innovation. Analyst activity mixed with insider purchase: Director bought 1,210 shares on May 4, 2026.
Xylem delivered Q1 2026 results with revenue of $2.1B, beating expectations and achieving 9% YoY adjusted EPS growth to $1.12 vs. $1.08 estimate. Net income margin expanded 90 basis points to 9.1%. Company maintained 2026 full-year adjusted EPS guidance of $5.35-$5.60 and 22.9-23.3% adjusted EBITDA margin. Announced $1.5B common stock repurchase authorization. Director Jerome Peribiere bought 1,210 shares on May 4 for $141,098.
Xylem reported Q1 2026 with revenue of $2.1B and EPS of $1.12, beating Wall Street forecast of $1.08. Adjusted EPS increased 9% YoY to $1.12 from $1.03 while organic revenue remained flat. Net income margin increased 90 bps to 9.1% with adjusted net income of $272M. Company forecasts FY2026 revenue of $9.2-$9.3B (up 2-3% reported basis). Adjusted EBITDA margin guidance $9.2-$9.3B. Management maintained 2026 guidance with continued margin expansion and EPS growth anticipated. Announced $1.5B common stock repurchase authorization effective Feb 25, 2026. Planned sale of international metering business outside North America to AURELIUS. Xylem and Global Water Intelligence estimate AI will drive 129% water demand increase by 2050, driven by power generation (54%), semiconductor fabrication (42%), and data center expansion (4%). Consensus Buy with 12-month PT $152.5 (32.15% upside). Recent analyst action: UBS downgrade to Neutral from Buy; JPMorgan lowered PT to $160 from $170.
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| XYLXYLEM | $111.75 | +2.80% | +0.4% | 17.8x | 1.08 | $25.8B |
| PHPARKER | $929.61 | +7.50% | +0.7% | 25.4x | 1.18 | $109.0B |
| ITWILLINOIS | $261.80 | +4.75% | +0.2% | 20.5x | 1.05 | $71.9B |
| GWWWW | $1,317.46 | +6.31% | -2.0% | 24.6x | 1.04 | $58.5B |
| DOVDOVER | $222.33 | +7.01% | -1.4% | 17.9x | 1.21 | $28.0B |
| IRINGERSOLL | $77.46 | +10.22% | +0.4% | 18.3x | 1.25 | $27.5B |
Price below 200d MA — bearish structure.